TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK)

Historical Holders from Q1 2014 to Q3 2025

Symbol
TAK on NYSE
Type / Class
Equity / SPONSORED ADS
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
85,178,126
Holdings value
$1,247,017,115
% of all portfolios
0.002%
Number of holders
319
Number of buys
185
Number of sells
-114
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of TAKEDA PHARMACEUTICAL CO LTD - SPONSORED ADS (TAK)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 85,178,126 $1,247,017,115 +$106,182,589 $14.64 319
2025 Q2 77,806,509 $1,202,785,823 +$106,862,917 $15.46 307
2025 Q1 71,086,493 $1,057,034,943 -$156,054 $14.87 300
2024 Q4 72,039,413 $953,847,647 -$55,374,045 $13.24 295
2024 Q3 71,553,169 $1,015,380,211 +$20,521,956 $14.22 295
2024 Q2 72,061,993 $940,730,985 -$86,515,519 $12.94 281
2024 Q1 78,179,293 $1,087,229,460 -$73,198,839 $13.89 310
2023 Q4 83,396,860 $1,190,086,769 +$34,664,126 $14.27 302
2023 Q3 80,437,115 $1,242,500,598 -$66,352,882 $15.47 310
2023 Q2 84,017,983 $1,320,003,579 -$935,677 $15.71 308
2023 Q1 82,262,152 $1,355,589,943 +$248,962,456 $16.48 296
2022 Q4 68,069,757 $1,063,701,562 +$48,470,698 $15.6 278
2022 Q3 63,905,792 $829,049,514 +$90,138,783 $12.97 258
2022 Q2 56,978,507 $799,748,914 +$66,260,391 $14.04 258
2022 Q1 56,159,628 $802,855,152 -$261,335,589 $14.32 265
2021 Q4 75,991,152 $1,037,422,048 -$299,110,798 $13.63 271
2021 Q3 91,971,894 $1,505,006,212 -$51,986,093 $16.38 274
2021 Q2 94,938,677 $1,598,252,322 -$223,745,245 $16.83 287
2021 Q1 107,728,479 $1,962,038,029 -$1,144,218 $18.26 300
2020 Q4 108,743,491 $1,978,272,193 +$47,411,066 $18.2 291
2020 Q3 107,411,892 $1,906,842,183 -$74,858,671 $17.84 296
2020 Q2 111,608,181 $2,000,687,993 -$67,870,563 $17.93 291
2020 Q1 115,527,636 $1,755,033,222 -$255,328,027 $15.18 290
2019 Q4 129,903,867 $2,564,492,170 -$263,257,024 $19.73 323
2019 Q3 142,713,146 $2,453,745,858 -$10,944,466 $17.2 296
2019 Q2 144,969,953 $2,567,070,888 -$508,563,867 $17.7 323
2019 Q1 178,446,454 $3,633,871,563 +$2,339,014,740 $20.37 365
2018 Q4 53,778,088 $908,062,778 +$853,769,936 $16.82 82
2018 Q3 2,916,735 $62,341,000 +$9,168,044 $21.37 15
2018 Q2 2,487,812 $52,101,000 +$10,712,473 $20.9 14
2018 Q1 1,890,639 $46,133,000 +$5,629,927 $24.41 10
2017 Q4 1,659,165 $47,189,000 +$7,825,480 $28.22 9
2017 Q3 1,383,979 $38,304,326 +$9,532,340 $27.4 8
2017 Q2 1,039,668 $26,417,135 +$3,307,044 $25.06 8
2017 Q1 909,540 $21,474,985 +$7,409,653 $23.24 8
2016 Q4 598,950 $12,441,746 +$257,312 $20.78 7
2016 Q3 586,683 $14,032,000 +$3,276,840 $23.81 6
2016 Q2 449,689 $9,685,809 -$5,868,979 $21.54 7
2016 Q1 722,721 $16,489,917 +$3,753,417 $22.82 8
2015 Q4 558,023 $13,979,103 +$8,524,753 $25 9
2015 Q3 231,769 $5,065,000 -$7,911,819 $21.87 9
2015 Q2 556,403 $13,466,000 +$636,075 $24.16 8
2015 Q1 529,554 $13,251,000 +$1,844,508 $25 8
2014 Q4 455,916 $9,476,000 -$83,574 $20.84 8
2014 Q3 459,996 $10,000,000 +$530,656 $21.75 8
2014 Q2 435,563 $10,116,000 -$6,899,910 $23.19 7
2014 Q1 726,088 $17,232,000 -$1,435,931 $23.75 9